Chugai Pharmaceutical Co., Ltd. (CHGCF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 12:16PM EDT
Loading interactive chart…
- Stockopedia
Four clues to the quality of Chugai Pharmaceutical Co (TYO:4519)
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that t...
- Business Wire
New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO, October 14, 2021--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced new longer-term efficacy and safety data for Enspryng® [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. The data show Enspryng has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spe
© 2022 Yahoo. All rights reserved.
